Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DV3WF1
|
|||
| Drug Name |
LMP400
|
|||
| Synonyms |
INDOTECAN; 915303-09-2; UNII-BTA69L5M8D; NSC-724998; BTA69L5M8D; 2,3-dimethoxy-6-(3-morpholinopropyl)-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; LMP-400; NSC724998; Indotecan(LMP400); Indotecan (LMP400); CHEMBL216462; SCHEMBL7712572; DTXSID90238613; BCP34018; EX-A3020; Indotecan hydrochloride (LMP-400); ZB1545; SB16793; HY-18351; CS-0007476; LMP400; LMP-400; LMP 400; Q27274872; 3-[(Morpholine)-1-propyl]-5,3-dimethoxy-8,9-meth ylenedioxy-5,11-dioxo-11H-indeno[1,2-c]isoquinoline
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-10: C81-C86; ICD-9: 202] | Phase 1 | [1] | |
| Neoplasm [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | ||
| Company |
LMP400
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H26N2O7
|
|||
| Canonical SMILES |
COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCN6CCOCC6)OC
|
|||
| InChI |
1S/C26H26N2O7/c1-31-19-10-15-18(13-20(19)32-2)26(30)28(5-3-4-27-6-8-33-9-7-27)24-16-11-21-22(35-14-34-21)12-17(16)25(29)23(15)24/h10-13H,3-9,14H2,1-2H3
|
|||
| InChIKey |
FMFIFGLHVOZDEL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 915303-09-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01794104) Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas. U.S. National Institutes of Health. | |||
| REF 2 | Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.